FDA Proposes Faster Path for Chewable OTC Drug Updates
Published Date: 6/5/2025
Notice
Summary
The FDA is making it easier for companies to switch certain OTC pills into chewable tablets, dissolving tablets, or films without extra paperwork. This helps drug makers update their products faster while keeping safety rules in check. If approved, these minor changes could save time and money for everyone involved.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Allow minor OTC dosage-form switches
If you make over‑the‑counter (OTC) monograph drugs, the FDA proposes allowing certain minor dosage form changes — from tablets or capsules to chewable tablets, orally disintegrating tablets, or films — without issuing a separate order to amend the OTC monograph or separately finding the new dosage form to be generally recognized as safe and effective (GRASE). This change applies only when the product conforms with the proposed order, the Federal Food, Drug, and Cosmetic Act, and other applicable requirements.
Speeds updates and cuts paperwork/costs
The proposed order is intended to let drug makers update certain OTC products faster and without extra paperwork, which the FDA says could save time and money for everyone involved. If finalized, manufacturers could implement eligible dosage‑form changes more quickly than under the current separate‑order process.
Dosage changes still subject to safety rules
The FDA says the minor dosage form changes are allowed only when the products conform with the proposed order, the Federal Food, Drug, and Cosmetic Act, and other applicable requirements, so safety and legal standards remain in force. That means companies cannot use this pathway unless they meet the same safety and statutory requirements described in the order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-10251 — Recommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs; Draft Guidance for Industry; Availability
Hey makers of over-the-counter solid pills! The FDA just dropped a draft guide to help you make small changes to your products without a headache. Follow these tips to stay on track, save time, and avoid extra costs while keeping your meds safe and sound.
Next: 2025-10253 — Over-the-Counter Monograph Condition B001: Single-Unit or Unit-Dose Containers for Over-the-Counter Monograph Drugs in Orally Disintegrating Tablet and Film Dosage Forms
The FDA wants to make sure certain over-the-counter medicines that dissolve in your mouth come in single-use packages. This change helps keep doses safe and easy to use, especially for kids and busy folks. If this rule passes, drug makers will need to update their packaging soon, which might cost a bit but will make medicine safer for everyone.